Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04597450 · ClinicalTrials.gov registry record · Phase 1
Lu AG06466 in Participants With Post Traumatic Stress Disorder (PTSD)
A Phase 1 study, sponsored by H. Lundbeck A/S.
- Completed
- Registry status
- Phase 1
- Development phase
- 35
- Enrollment target
NCT04597450 is a Phase 1 study that has completed, run by H. Lundbeck A/S. The registered enrollment target is 35 participants.
The verdict
NCT04597450, a Phase 1 study, has completed, sponsored by H. Lundbeck A/S.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 35 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the effect of Lu AG06466 after multiple doses of 30 milligrams (mg) in participants with PTSD.
Interventions
- DRUG Placebo
- DRUG Lu AG06466
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2020-09-30 |
| Est. Completion | 2023-02-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04597450
The ClinicalTrials.gov registry entry for NCT04597450 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lundbeck A/S, which has 72 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04597450 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04597450 about?
NCT04597450 is a clinical study titled "Lu AG06466 in Participants With Post Traumatic Stress Disorder (PTSD)". The purpose of this study is to investigate the effect of Lu AG06466 after multiple doses of 30 milligrams (mg) in participants with PTSD.
What is the current status of trial NCT04597450?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2020-09-30. Estimated completion is 2023-02-13.
What interventions are being tested in trial NCT04597450?
The interventions under investigation include: Placebo (DRUG), Lu AG06466 (DRUG).
Who is sponsoring clinical trial NCT04597450?
This trial is sponsored by H. Lundbeck A/S, which has 72 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.